RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

VIA Pharmaceuticals Revenue 2024

VIA Pharmaceuticals Revenue

-9,291.51 TT USD

VIA Pharmaceuticals Dividend yield

Ticker

VIAP

ISIN

US92554T1034

In 2024, VIA Pharmaceuticals's sales reached -9,291.51 TT USD, a 0% difference from the 0 USD sales recorded in the previous year.

The VIA Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2011e-9.29 T-0,00
2010--
2009--
2008--
2007--
2006--
20050.0896,39
20040.08100,00
20030.04100,00
20021.12100,00
20010.3100,00
20000.16100,00
19990.1266,67
19980.1942,11
19970.1942,11
1996--

VIA Pharmaceuticals Aktienanalyse

What does VIA Pharmaceuticals do?

VIA Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company was founded in 1999 in San Francisco. The vision of VIA Pharmaceuticals from the beginning was to develop more innovative therapies for the treatment of cardiovascular diseases that are more effective and have fewer side effects compared to existing treatment options. The company focuses on the discovery and exploration of new active substances and technologies that target the causes of cardiovascular diseases. VIA Pharmaceuticals' business model is based on collaboration with other biopharmaceutical companies and research institutes. For example, the company collaborates with the Cleveland Clinic and the University of California to advance the development of new drugs. Collaboration with investors and financial institutions also plays an important role in VIA Pharmaceuticals' business model. The various divisions of VIA Pharmaceuticals specialize in the treatment of cardiovascular diseases. In particular, drugs for the treatment of atherosclerosis, one of the main causes of cardiovascular diseases, are being developed. VIA Pharmaceuticals' research focuses on reducing inflammation and blood lipids. The products of VIA Pharmaceuticals are currently still in clinical development. One of the most promising products of the company is VIA-2291, a drug for the treatment of atherosclerosis. The drug specifically targets inflammation in blood vessels, reducing the risk of plaques and thrombosis. VIA-2291 has already shown promising results in clinical trials and is currently in phase 3 of clinical development. Other products of VIA Pharmaceuticals are in various stages of clinical development. Overall, VIA Pharmaceuticals is an innovative biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company relies on collaboration with other research institutes and biotech companies. The products of VIA Pharmaceuticals are currently still in clinical development but show promising results and could contribute to making the treatment of cardiovascular diseases more effective and with fewer side effects in the future. VIA Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding VIA Pharmaceuticals's Sales Figures

The sales figures of VIA Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing VIA Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize VIA Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in VIA Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about VIA Pharmaceuticals Stock

How much revenue did VIA Pharmaceuticals generate this year?

VIA Pharmaceuticals has achieved a revenue of -9,291.51 TT USD this year.

How much was the turnover of the company VIA Pharmaceuticals compared to the previous year?

The revenue of VIA Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of VIA Pharmaceuticals?

The revenue of VIA Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of VIA Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of VIA Pharmaceuticals so important for investors?

The revenue of VIA Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does VIA Pharmaceuticals pay?

Over the past 12 months, VIA Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, VIA Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of VIA Pharmaceuticals?

The current dividend yield of VIA Pharmaceuticals is .

When does VIA Pharmaceuticals pay dividends?

VIA Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of VIA Pharmaceuticals?

VIA Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of VIA Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is VIA Pharmaceuticals located?

VIA Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIA Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIA Pharmaceuticals from 5/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/22/2024.

When did VIA Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/22/2024.

What was the dividend of VIA Pharmaceuticals in the year 2023?

In the year 2023, VIA Pharmaceuticals distributed 0 USD as dividends.

In which currency does VIA Pharmaceuticals pay out the dividend?

The dividends of VIA Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VIA Pharmaceuticals

Our stock analysis for VIA Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VIA Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.